✦ LIBER ✦

Phase 1 study of high-dose hydroxyurea in lung cancer

✍ Scribed by D. Veale; B. M. J. Cantwell; N. Kerr; A. Upfold; A. L. Harris

Publisher: Springer
Year: 1988
Tongue: English
Weight: 383 KB
Volume: 21
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00262739

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of high-dose aclarubicin

Phase II study of high-dose aclarubicin in previously treated patients with small-cell lung cancer

✍ Peter Buhl Jensen; Susanne Kornum Larsen; Irene Stilbo 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 230 KB

Phase 1/11 study of misonidazole in stag

Phase 1/11 study of misonidazole in stage III lung cancer

✍ C.J.H. Fryer; G. Gudauskas; B. Driedger; C. Dedhar 📂 Article 📅 1984 🏛 Elsevier Science 🌐 English ⚖ 141 KB

A phase I/II study of weekly high-dose e

A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer

✍ Daniel T. Milton; Christopher G. Azzoli; Robert T. Heelan; Ennapadam Venkatraman 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB 👁 2 views

Phase II feasibility study of high dose

Phase II feasibility study of high dose epirubicin plus etoposide and cisplatin (HDEEC) regimen in small cell lung cancer

✍ Rafael Rosell; Juan Carles; Albert Abad; Jose M. Jimeno; Isabel Moreno; Agustin 📂 Article 📅 1992 🏛 Springer US 🌐 English ⚖ 472 KB

A phase II study of high-dose estrogens

A phase II study of high-dose estrogens (diethylstilbestrol diphosphate) in prostate cancer

✍ Dennis L. Citrin; Merrill S. Kies; Carl-Bertil Wallemark; Jan Khandekar; Edward 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 337 KB 👁 2 views

A phase II study of high-dose medroxypro

A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer

✍ Geoffrey Falkson; Hèndré C. Falkson 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 215 KB

Twenty-three evaluable patients with advanced breast cancer were treated with MPA, 1,400 mg/m2 daily PO for the first 6 months, and 500 mg/m2 daily PO thereafter. The median total dose was 191,400 mg in 88 days, with the maximum dose given to date 522,600 mg in 282 days. Most patients tolerated high